Latest autoimmune disease Stories
LA JOLLA, Calif. and SHANGHAI, May 16, 2013 /PRNewswire/ -- RuiYi Inc. announced today that it has entered into an exclusive license and collaborative development agreement with Genor BioPharma for the development of RYI-008 in China. RYI-008 is a novel anti-IL-6 monoclonal antibody with a unique pharmacologic profile that has the potential to define a new paradigm in the treatment of autoimmune diseases and cancer. "RYI-008, with its unprecedented femtamolar potency and amazing long...
May is Celiac Awareness Month and local San Antonio internal medicine practice, Digestive & Liver Disease Center of San Antonio, advises on the disorder. San Antonio, TX (PRWEB) May 14, 2013 Digestive & Liver Disease Center of San Antonio encourages the public to advocate for Celiac Awareness Month in May. Celiac disease is an autoimmune disorder triggered by the ingestion of gluten, a protein found in wheat, barley and rye. An estimated 1 in 141 Americans has celiac disease, yet...
Innovative and high quality product lines set new benchmarks for the autoimmune disease diagnostics market LONDON, April 30, 2013 /PRNewswire/ -- Based on its recent analysis of the autoimmune disease diagnostics market, Frost & Sullivan recognises Euro Diagnostica AB with the 2013 Europe Product Differentiation Excellence Award. "Euro Diagnostica offers a range of high-quality enzyme linked immunosorbent assay (ELISA) kits for autoimmune diagnostics," noted Frost &...
BETHESDA Md., April 25, 2013 /PRNewswire/ -- TNI BioTech, Inc. (OTC PINK: TNIB) is pleased to announce that they have named Terry Lierman from the Summit Global Ventures as a strategic advisor to the company. In this capacity, Mr. Lierman will provide strategic and tactical direction to improve operational productivity for the company's growth plans. "Terry Lierman is renowned on capitol hill for both his political skills and his passionate support of improved healthcare and funding...
BETHESDA, Md., April 22, 2013 /PRNewswire/ -- TNI BioTech, Inc. (OTC Pink: TNIB) (www.tnibiotech.com), announced it has filed its Form 10 to become a fully reporting public company with the Securities and Exchange Commission. Some of the highlights of the filing are the acquisition and licensing agreements between TNI BioTech and Dr. Nicholas P. Plotnikoff, Dr. Bernard Bihari, Professor Fengping Shan, Dr. Jill Smith and LDN Research LLC, and Pennsylvania State University. In...
Heidi M. Hagen, a noted authority on Biotech Cell Manufacturing, Joins as Head of Global Operations Strategy NEW YORK, April 11, 2013 /PRNewswire-iReach/ -- SOTIO a.s, a leader in cell therapy treatments for cancer and autoimmune diseases, has added to their senior leadership team with the addition of Heidi M. Hagen as Chief Operating Officer-US and Head of Global Operations Strategy. As the strategic advisor to SOTIO, Epsen Fuller Group completed the successful placement, which...
SAN DIEGO, April 5, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today the initiation of dosing in a Phase 1 clinical trial of APD334, a novel oral drug candidate that targets the sphingosine 1-phosphate subtype 1 (S1P(1)) receptor for the potential treatment of autoimmune diseases. This randomized, double-blind and placebo-controlled Phase 1 trial will evaluate the safety, tolerability and pharmacokinetics of single-ascending doses of APD334 in up to 64...
-- European Clinical Trial Application Submission Expected in the Second Quarter of 2013 -- SEATTLE, March 28, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced data from toxicology studies evaluating OMS721, the lead human monoclonal antibody in Omeros' mannan-binding lectin-associated serine protease-2 (MASP-2) program. In non-human primates and rodents, there were no drug-related findings in the toxicology assessments, including gross pathology, histopathology...
Neurons that control hunger in the central nervous system also regulate immune cell functions, implicating eating behavior as a defense against infections and autoimmune disease development, Yale School of Medicine researchers have found in a new study published in the Proceedings of the National Academy of Sciences (PNAS). Autoimmune diseases have been on a steady rise in the United States. These illnesses develop when the body's immune system turns on itself and begins attacking its own...
BREDA, The Netherlands and GHENT, Belgium, March 25, 2013 /PRNewswire/ -- ARGX-112 targets IL22R1, a novel target involved in chronic skin inflammation arGEN-X, a clinical stage biopharmaceutical company specialized in the discovery and development of highly differentiated human monoclonal antibody therapeutics, announces that it has progressed ARGX-112, its fourth therapeutic candidate, into formal preclinical development. ARGX-112 is a novel, fully human...
